An average trading volume for Health Catalyst Inc. (HCAT) has been steady over the recent period.

The price of Health Catalyst Inc. (NASDAQ: HCAT) closed at $13.38 in the last session, up 3.80% from day before closing price of $12.89. In other words, the price has increased by $+0.49 from its previous closing price. On the day, 672840 shares were traded. HCAT stock price reached its highest trading level at $13.47 during the session, while it also had its lowest trading level at $12.61.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



We take a closer look at HCAT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.51.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on January 03, 2023, Downgraded its rating to In-line and sets its target price to $11 from $10 previously.

On October 31, 2022, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $10.

RBC Capital Mkts Downgraded its Outperform to Sector Perform on October 25, 2022, whereas the target price for the stock was revised from $19 to $9.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 18 when Hunt Bryan Truman sold 2,354 shares for $12.53 per share. The transaction valued at 29,503 led to the insider holds 136,937 shares of the business.

Hunt Bryan Truman sold 2,055 shares of HCAT for $24,660 on Jan 17. The Chief Financial Officer now owns 139,291 shares after completing the transaction at $12.00 per share. On Jan 17, another insider, Llewelyn Linda, who serves as the Chief People Officer of the company, sold 642 shares for $12.12 each. As a result, the insider received 7,781 and left with 49,707 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 2.66 while its Price-to-Book (P/B) ratio in mrq is 1.65.

Stock Price History:

Over the past 52 weeks, HCAT has reached a high of $31.08, while it has fallen to a 52-week low of $6.40. The 50-Day Moving Average of the stock is 10.47, while the 200-Day Moving Average is calculated to be 13.04.

Shares Statistics:

According to the various share statistics, HCAT traded on average about 821.01K shares per day over the past 3-months and 649.18k shares per day over the past 10 days. A total of 54.30M shares are outstanding, with a floating share count of 53.02M. Insiders hold about 3.40% of the company’s shares, while institutions hold 91.90% stake in the company. Shares short for HCAT as of Oct 13, 2022 were 2.75M with a Short Ratio of 1.66M, compared to 2.53M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.02% and a Short% of Float of 5.05%.

Earnings Estimates

The company has 13 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.35, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.07 and low estimates of -$0.3.

Analysts are recommending an EPS of between -$0.3 and -$0.73 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.35, with 14 analysts recommending between -$0.1 and -$1.05.

Revenue Estimates

A total of 15 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $275.3M, while the lowest revenue estimate was $272.59M, resulting in an average revenue estimate of $273.97M. In the same quarter a year ago, actual revenue was $241.93M, up 13.20% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $295.59M in the next fiscal year. The high estimate is $303M and the low estimate is $281.57M. The average revenue growth estimate for next year is up 7.90% from the average revenue estimate for this year.